Similarly, de novo triglyceride (TG) synthesis driven by glycerol‐3‐phosphate acyltransferase 3 can stimulate the NF‐κB/BCL‐2 antiapoptotic signaling pathway, leading to the resistance of hepatocellular carcinoma (HCC) cells to sorafenib treatment [28]. Here, BCL2 is linked to hepatocellular carcinoma.